JFD, a world leader in breathing apparatus, life support equipment and hyperbaric medical equipment to support life-critical applications and part of James Fisher and Sons plc, today announced that it will bring to market a new patient ventilator system to support global health systems in combatting the COVID-19 pandemic.
JFD has responded to the UK Government’s Rapidly Manufactured Ventilator System call to manufacturers, to support the provision of essential medical equipment to the front-line NHS.
The InVicto™ ventilator is more advanced than CPAP (Continuous Positive Airway Pressure) systems; it has been fully developed, including full in-house testing, and is ready for launch into full scale production and global distribution. The InVicto™ system can support global healthcare services by reducing pressure on intensive care unit (ICU) facilities, helping to save lives as the virus approaches its peak in many countries.
JFD has engineered the InVicto™ ventilator system, with extensive testing conducted in the JFD breathing laboratories.
The InVicto™ is suitable for deployment in many scenarios due to its flexible design. This could be in a pre-critical temporary ward or care home, providing an enhanced breathing ventilation aid that offers an improvement over CPAP treatment. The system extends to full hospital ward capability providing full ventilation support with patient monitoring, breathing gas and O2 management and alarms.
JFD has designed the system with a specific focus on reducing the usage of O2. For InVicto™, it has applied its world leading expertise in breathing gas reclaim systems for the offshore diving industry. InVicto™ uses up to 90% less O2 than other ventilators available on the market. Due to exceptional demand and logistical challenges in supply driven by the onset of the COVID Pandemic, JFD considered that O2 could likely become an increasingly scarce resource to provide at scale. Therefore, the design philosophy was to also produce a ventilator which operates with minimal O2 consumption.